Known targets — ChEMBL curated mechanism
PPARDPTGS1PTGS2dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Tyrosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.41 |
| ▸ | PTGS2 known ✓ | P35354 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | GSR | P00390 | 2/20 | 0.47 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.43 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.43 |
| ▸ | GRM8 | O00222 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.42 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL28098884 | 1.00 | SLC7A5 (0.56) | SLC7A5THRBITGB3ITGA2BGSR | |
| Tyrosine SCHEMBL19712182 | 1.00 | SLC7A5 (0.56) | SLC7A5THRBITGB3ITGA2BGSR | |
| Tyrosine SCHEMBL19712178 | 1.00 | SLC7A5 (0.56) | SLC7A5THRBITGB3ITGA2BGSR | |
| Tyrosine SCHEMBL1649464 | 0.99 | SLC7A5 (0.57) | SLC7A5THRBITGB3ITGA2BGSR | |
| Tyrosine SCHEMBL26598018 | 0.99 | SLC7A5 (0.57) | SLC7A5THRBITGB3ITGA2BGSR | |
| Tyrosine SCHEMBL1921493 | 0.99 | SLC7A5 (0.57) | SLC7A5THRBITGB3ITGA2BGSR | |
| Tyrosine SCHEMBL1696965 | 0.94 | SLC7A5 (0.63) | SLC7A5THRBITGB3ITGA2BGSR | |
| Tyrosine SCHEMBL29062530 | 0.94 | SLC7A5 (0.63) | SLC7A5THRBITGB3ITGA2BGSR | |
| Tyrosine SCHEMBL3513723 | 0.93 | SLC7A5 (0.65) | SLC7A5THRBITGB3ITGA2BGSR | |
| Tyrosine SCHEMBL530008 | 0.93 | SLC7A5 (0.65) | SLC7A5THRBITGB3ITGA2BGSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 15037 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746852-A1 | LIPID AGGREGATES FOR INTRAARTICULAR ADMINISTRATION | Universität Bern (CH) | 2026-05-27 | — | — | EP | claimed |
| US-20260139041-A1 | SUPPRESSION OF NEURODEGENERATIVE DISEASES BY SINGLE DOMAIN ANTIBODY | SINGH BIOTECHNOLOGY, LLC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026107075-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS WITH CD19-CD20 DUAL CAR-T CELLS | GENENTECH, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260124148-A1 | POLYPEPTIDE FORMULATIONS FOR ORAL DELIVERY | BHAMIS RES LABORATORY PVT LTD (IN) | 2026-05-07 | — | — | US | claimed |
| EP-3600553-B1 | GLATIRAMER DEPOT SYSTEMS FOR TREATING PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS | MAPI PHARMA LTD (IL) | 2026-05-06 | — | — | EP | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| EP-4709725-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20260060974-A1 | THERAPEUTIC TYROSINE KINASE INHIBITORS FOR MULTIPLE SCLEROSIS | PRINCIPIA BIOPHARMA INC. (US) | 2026-03-05 | — | — | US | claimed |
| CN-121586573-A | Lipopolymers for intra-articular administration | 伯尔尼大学 | 2026-02-27 | — | — | CN | claimed |
| US-20030064915-A1 | Therapeutic peptides for demyelinating conditions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-04-03 | — | — | US | claimed |
| US-20030055054-A1 | CXCR3 antagonists | TULARIK, INC. | 2003-03-20 | — | — | US | claimed |
| WO-2003005951-A2 | DRUG DELIVERY SYSTEM FOR ZERO ORDER, ZERO ORDER-BIPHASIC, ASCENDING OR DESCENDING DRUG DELIVERY | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-01-23 | — | — | WO | claimed |
| US-20020169159-A1 | An acetamide derivative is useful for treatment of inflammatory and immune conditions and diseases; modulates the expressin and/or function of a chemokine receptor | TULARIK INC. (US) | 2002-11-14 | — | — | US | claimed |
| WO-2002083143-A1 | CXCR3 ANTAGONISTS | TULARIK INC. (US) | 2002-10-24 | — | — | WO | claimed |
| WO-2002062750-A1 | CANNABINOID RECEPTOR LIGANDS | SCHERING CORPORATION (US) | 2002-08-15 | — | — | WO | claimed |
| WO-2002059143-A2 | THERAPEUTIC PEPTIDES FOR DEMYELINATING CONDITIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2002-08-01 | — | — | WO | claimed |
| EP-1187612-A1 | USE OF RILUZOLE FOR THE TREATMENT OF MULTIPLE SCLEROSIS | VERENIGING VOOR CHRISTELIJK WETENSCHAPPELIJK ONDERWIJS (NL) | 2002-03-20 | — | — | EP | claimed |
| WO-2001097785-A2 | BASIC COPOLYMERS FOR THE TREATMENT OF PRION-RELATED-DISEASE | CAPRION PHARMACEUTICALS INC. (CA) | 2001-12-27 | — | — | WO | claimed |
| WO-2000074676-A1 | USE OF RILUZOLE FOR THE TREATMENT OF MULTIPLE SCLEROSIS | VERENIGING VOOR CHRISTELIJK WETENSCHAPPELIKJK ONDERWIJS (US) | 2000-12-14 | — | — | WO | claimed |